2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2532

Changes In Quality Of Life In The First 5 Years Of Disease In The Systemic Lupus Erythematosus International Collaborating Clinics (SLICC) Cohort
Abstract Number: 275

Changes In Serum IL-18 Level In Systemic Juvenile Idiopathic Arthritis Patients Who Attained Drug-Free Remission By Tocilizumab
Abstract Number: 2000

Changes In The Prevalence Of Gout In The United States General Population Between 1960 and 2010: The National Health and Nutrition Examination Surveys
Abstract Number: 333

Changes In Weight Associated With Tumour Necrosis Factor Inhibition In Psoriatic Arthritis
Abstract Number: 39

Chaperone-Mediated Autophagy As a Target Of Therapeutic P140 Peptide Used In Lupus
Abstract Number: 1390

Chaperonin Protein 14-3-3n (eta) In Rheumatoid Arthritis and Arthritogenic Viral Infections
Abstract Number: 2794

Characterisation Of Antigens Driving In Situ Autoantibody Production In Human Lupus Tubulointerstitial Nephritis (TIN)
Abstract Number: 2051

Characteristics and Comparison Of Patients With Cystic Fibrosis With and Without Arthritis
Abstract Number: 1070

Characteristics and Medication Use Patterns Among Belimumab Users In a Commercially Insured Population With Systemic Lupus Erythematosus
Abstract Number: 606

Characteristics Of Lupus Nephritis: Data From a Large Multicenter Registry Of Patients With Systemic Lupus Erythematosus
Abstract Number: 426

Characteristics of Protocol-Specified Responders/Non-Responders Treated With Etanercept Plus Methotrexate in Period 1 of the Prize Study
Abstract Number: 1620

Characterization Of a Jamaican Lupus Cohort: Proinflammatory Biomarkers and Disease Activity
Abstract Number: 1692

Characterization Of Changes In Gene Expression and Inflammatory Proteins In Systemic Juvenile Idiopathic Arthritis Patients On Canakinumab Therapy
Abstract Number: 2648

Characterization Of Histidyl-tRNA Synthetase Specific Th Cell Response In Blood and Broncheoalveolar Lavage (BAL) Of Myositis Patients
Abstract Number: 1902

Characterization Of HLA-DRB1 Distribution By 3rd Hypervariable Region Sequence In Systemic Sclerosis and Control Populations

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].